ClinicalTrials.gg

Program

Ritonavir

Also written as “ritonavir”, “PF-07321332/ritonavir” and “RTV”.

Its studies are mostly in HIV Infections · Hepatitis C · COVID-19 · Hepatitis C, Chronic · Acquired Immunodeficiency Syndrome, led by 6 companies.

Furthest: phase 4, since Sep 28, 200783 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim320 open or runningphase 4since Sep 28, 2007Mar 19, 2003none ahead
Hoffmann-La Roche230 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Bristol-Myers Squibb190 open or runningphase 4since Oct 3, 2006May 6, 2002none ahead
Abbott60 open or runningphase 3since May 31, 2002Nov 2, 1999none ahead
eiger-biopharmaceuticals20 open or runningphase 3since Oct 18, 2018Nov 15, 2016none ahead
ppd-development-lp10 open or runningphase 3since Oct 10, 2000Oct 10, 2000none ahead

Also a collaborator on its studies: almedis, Pfizer, tibotec-therapeutics-a-division-of-ortho-biotech-products-l-, tibotec-pharmaceutical-limited, Shionogi and trimeris.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 27 studies since Aug 16, 2006.

  1. May 3, 2012Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT01591850 · 51 enrolled · United States
  2. Jun 6, 2012Phase 1 study in HIV InfectionsHoffmann-La Roche · NCT01638650 · 23 enrolled · United Kingdom
  3. Jun 22, 2012Phase 2 study in Hepatitis C, ChronicHoffmann-La Roche · NCT01628094 · 110 enrolled · United States, Australia, Germany and more
  4. Sep 21, 2012Phase 4 study in HIV, PediatricBristol-Myers Squibb · NCT01691794 · 108 enrolled · United States, Argentina, Brazil and more
  5. Jun 6, 2014Phase 1 study in Hepatitis CBristol-Myers Squibb · NCT02159352 · 49 enrolled · United States
  6. Jul 18, 2014Phase 1 study in HealthyBoehringer Ingelheim · NCT02195466 · 20 enrolled
  7. Aug 26, 20143 phase 1 studies in HealthyBoehringer Ingelheim · NCT02227017, NCT02226991, NCT02226978
  8. Aug 28, 2014Phase 2 study in HIV InfectionsBoehringer Ingelheim · NCT02229760 · 3 enrolled
  9. Sep 11, 20142 phase 2 studies in HIV InfectionsBoehringer Ingelheim · NCT02239835, NCT02251223
  10. Sep 18, 201415 phase 1 studiesBoehringer Ingelheim · NCT02245451, NCT02245438, NCT02245269 and 12 more
  11. Oct 2, 20143 phase 1 studies in HealthyBoehringer Ingelheim · NCT02257021, NCT02256826, NCT02256774
  12. Dec 17, 2014Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT02321384 · 100 enrolled · Netherlands
  13. Nov 15, 2016eiger-biopharmaceuticals's first study: phase 2 study in Hepatitis D, ChronicNew to eiger-biopharmaceuticalseiger-biopharmaceuticals · NCT02968641
  14. Oct 18, 2018Phase 3 study in Hepatitis Deiger-biopharmaceuticals · NCT03719313 · 407 enrolled · United States, Belgium, Bulgaria and more

TargetBeta

“Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 83 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT03719313Hepatitis D · United States, Belgium, Bulgaria and more3Completedeiger-biopharmaceuticalsOct 6, 2022407
NCT02968641Hepatitis D, Chronic2Withdrawneiger-biopharmaceuticalsFeb 12, 20210
NCT02321384Healthy Volunteer · Netherlands1TerminatedHoffmann-La RocheNov 26, 2015100
NCT02257021Healthy1CompletedBoehringer IngelheimMay 200534
NCT02256826Healthy1CompletedBoehringer IngelheimJun 200534
NCT02256774Healthy1CompletedBoehringer IngelheimMay 200551
NCT02253953Healthy1CompletedBoehringer IngelheimDec 200362
NCT02253914Healthy1CompletedBoehringer IngelheimDec 2004100
NCT02253901Healthy1CompletedBoehringer IngelheimMay 200533
NCT02253875Healthy1CompletedBoehringer IngelheimFeb 200615
NCT02253862Healthy1CompletedBoehringer IngelheimMar 200617
NCT02253836Healthy1CompletedBoehringer IngelheimJul 200521
NCT02253797Healthy1CompletedBoehringer IngelheimJul 2003
NCT02251223HIV Infections2CompletedBoehringer IngelheimFeb 2002208
NCT02251158Healthy1CompletedBoehringer IngelheimDec 200330
NCT02251145Healthy1CompletedBoehringer IngelheimJun 200249
NCT02251119Healthy1CompletedBoehringer IngelheimJan 200324
NCT02259855Hepatic Insufficiency1CompletedBoehringer IngelheimOct 1, 200836
NCT02245451Healthy1CompletedBoehringer IngelheimFeb 200515
NCT02245438Healthy1TerminatedBoehringer IngelheimJun 200252
NCT02245269Healthy1CompletedBoehringer IngelheimOct 200323
NCT02244190Healthy1CompletedBoehringer IngelheimMay 200832
NCT02239835HIV Infections2TerminatedBoehringer IngelheimNov 200179
NCT02229760HIV Infections2TerminatedBoehringer IngelheimSep 20073
NCT02227017Healthy1CompletedBoehringer IngelheimApr 200635
NCT02226991Healthy1CompletedBoehringer IngelheimJul 200634
NCT02226978Healthy1CompletedBoehringer IngelheimMay 200729
NCT02195466Healthy1CompletedBoehringer IngelheimJul 200320
NCT02159352Hepatitis C · United States1CompletedBristol-Myers SquibbJul 201449
NCT01691794HIV, Pediatric · United States, Argentina, Brazil and more4CompletedBristol-Myers SquibbOct 31, 2014108
NCT01628094Hepatitis C, Chronic · United States, Australia, Germany and more2CompletedHoffmann-La RocheNov 2013110
NCT01638650HIV Infections · United Kingdom1CompletedHoffmann-La RocheJun 201223
NCT01591850Healthy Volunteer · United States1CompletedHoffmann-La RocheNov 201151
NCT01592318Healthy Volunteer · New Zealand1CompletedHoffmann-La RocheJun 201242
NCT01592305Healthy Volunteer · United States1CompletedHoffmann-La RocheJun 201240
NCT01588002Healthy Volunteer · United States1CompletedHoffmann-La RocheJun 201240
NCT01519336Healthy Volunteer · United States1CompletedHoffmann-La RocheMar 201240
NCT01531647Healthy Volunteer · United States1CompletedHoffmann-La RocheMar 201220
NCT01514968Healthy Volunteer · United States1CompletedHoffmann-La RocheFeb 201218
NCT01483742Hepatitis C, Chronic · United States, Australia, Canada and more2CompletedHoffmann-La RocheSep 201343
NCT01483729Healthy Volunteer · New Zealand1CompletedHoffmann-La RocheJan 201236
NCT01418274Healthy Volunteer · United States1CompletedHoffmann-La RocheSep 201120
NCT01392755Healthy Volunteer · United States1CompletedHoffmann-La RocheSep 201132
NCT01389544Healthy Volunteer · United States1CompletedHoffmann-La RocheJul 201118
NCT01374802HIV Infections · Germany1CompletedBoehringer IngelheimJul 201114
NCT01335698HIV · United States, Argentina, Brazil and more3CompletedBristol-Myers SquibbSep 10, 2014160
NCT01232127HIV · Germany, United Kingdom4CompletedBristol-Myers SquibbJun 201125
NCT01185860Hepatitis C, Chronic · France, New Zealand, Poland1CompletedHoffmann-La RocheJan 201259
NCT01185873Healthy Volunteer · United States, Czech Republic, Slovakia1CompletedHoffmann-La RocheDec 201381
NCT01099579HIV Infections · Brazil, Chile, Mexico and more3CompletedBristol-Myers SquibbOct 4, 201282
NCT00833482Acquired Immunodeficiency Syndrome · United States, Netherlands1CompletedBristol-Myers SquibbJul 2010185
NCT00646776Antivirals/HIV · United States1CompletedBristol-Myers SquibbAug 200885
NCT00623597HIV Infections · Argentina, Spain, Thailand2CompletedHoffmann-La RocheMar 201018
NCT00552240HIV Infections · United States4CompletedBoehringer IngelheimMar 2010154
NCT00530920HIV Infections · Germany, Italy, Spain2CompletedBoehringer IngelheimMay 200885
NCT00517192HIV Infections · United States, Bahamas, Belgium and more3TerminatedBoehringer IngelheimSep 200840
NCT00435929HIV Infections · United States, Canada, Puerto Rico1CompletedHoffmann-La RocheNov 200916
NCT00393328HIV Infections · United States1CompletedBristol-Myers SquibbDec 200646
NCT00384904HIV Infections · United States, United Kingdom4CompletedBristol-Myers SquibbDec 200740
NCT00365339HIV Infections · United States1CompletedBristol-Myers SquibbJun 200640

How it is read

Names in the registry

  • “Ritonavir”, 80 entries
  • “ritonavir”, 35 entries
  • “PF-07321332/ritonavir”, 9 entries
  • “RTV”, 6 entries
  • “ombitasvir/paritaprevir/ritonavir and dasabuvir”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.